Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.44 | 0.05 | -0.00 | 1.68 |
| FCF Yield | -8.44% | -20.20% | -505.95% | -0.13% |
| EV / EBITDA | -14.48 | -6.31 | -0.78 | -1,534.25 |
| Quality | ||||
| ROIC | -69.33% | -78.03% | -71.83% | -24.64% |
| Gross Margin | 45.65% | 53.87% | 54.86% | 67.27% |
| Cash Conversion Ratio | 0.73 | 0.80 | 0.72 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.61% | -8.80% | -10.93% | -2.37% |
| Free Cash Flow Growth | 10.01% | 0.13% | -107.29% | -388.33% |
| Safety | ||||
| Net Debt / EBITDA | -1.61 | -0.59 | -0.58 | 1.15 |
| Interest Coverage | -4.31 | -9.09 | -14.28 | -24.03 |
| Efficiency | ||||
| Inventory Turnover | 2.15 | 2.00 | 2.32 | 2.09 |
| Cash Conversion Cycle | 167.85 | 176.86 | 145.24 | 161.76 |